Skip to main content

Hair-Loss Patients Lose In Taxotere MDL

Hair-Loss Patients Lose In Taxotere MDL

Hair-Loss Patients Lose In Taxotere MDL

Introduction

On Thursday, Louisiana Federal Judge Jane Triche Milazzo rejected reconsidering lawsuits filed by two Taxotere patients who alleged drugmaker Sanofi-Aventis for failing to inform about permanent hair loss.

The judge passed the judgment after finding that their cases were filed too late under Louisiana law. The plaintiffs had made use of the class action's master complaint. According to the permanent chemotherapy-induced alopecia (PCIA) parameter, hair loss is diagnosable six months after chemo ends. Last July, the judge ruled that at the six-month mark, a second yearlong clock for filing suits begins.

The judge considering the timeline's evidence reached the ruling, as the Louisiana law on statutes of limitations, called prescription law, allows a one-year “prescriptive period” in product liability disputes.

Multiple drug companies, along with Sanofi, are facing 10,000 cases in the multidistrict litigation. The lawsuits are consolidated under MDL No. 2740 before U.S. District Judge Jane Triche Milazzo.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

First Federal Bellwether Trial Set in Strattice Mesh Case

Categories: Hernia Mesh

Lawyers involved in federal Strattice hernia mesh litigation are scheduled to meet with the presiding judge in the U.S. District Court for the District of New Jersey to…

Tepezza Hearing Loss Trial Set for June 2026

Categories: Tepezza

The U.S. District Judge overseeing all federal Tepezza lawsuits has postponed the start of the first bellwether trial by 60 days.

This decision comes as attorneys…

FDA Moves to Restrict Dangerous 7-OH Opioid Products

Categories: Opioids

In a significant move to combat the ongoing opioid crisis, the U.S. Food and Drug Administration (FDA) has recommended a scheduling action under the Controlled Substances Act (CSA) to regulate certain products containing 7-hydroxymitragynine (7-…

✍️ FREE — 2,800 Pages Legal Process Outsourcing Trial!                 
No Contract. No Risk — Full Mass Tort + LPO Access, Free!

Only 10 Firms Accepted—Offer Ends August 31!